The estimated Net Worth of Kevin W Quinlan is at least $844 Thousand dollars as of 27 March 2013. Kevin Quinlan owns over 18,374 units of Pressure BioSciences stock worth over $746 and over the last 20 years Kevin sold PBIO stock worth over $843,000.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Kevin Quinlan PBIO stock SEC Form 4 insiders trading
Kevin has made over 8 trades of the Pressure BioSciences stock since 2005, according to the Form 4 filled with the SEC. Most recently Kevin sold 18,374 units of PBIO stock worth $206,524 on 27 March 2013.
The largest trade Kevin's ever made was exercising 136,000 units of Pressure BioSciences stock on 11 February 2005 worth over $388,960. On average, Kevin trades about 13,610 units every 174 days since 2005. As of 27 March 2013 Kevin still owns at least 27,112 units of Pressure BioSciences stock.
You can see the complete history of Kevin Quinlan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Quinlan's mailing address?
Kevin's mailing address filed with the SEC is C/O ANIKA THERAPEUTICS, INC., 160 NEW BOSTON STREET, WOBURN, MA, 01801.
Insiders trading at Pressure BioSciences
Over the last 21 years, insiders at Pressure BioSciences have traded over $0 worth of Pressure BioSciences stock and bought 433,961 units worth $321,010 . The most active insiders traders include Gregory Gene Freitag, Richard T Schumacher, and Kevin W Quinlan. On average, Pressure BioSciences executives and independent directors trade stock every 111 days with the average trade being worth of $342. The most recent stock trade was executed by Bradford Addison Young on 31 December 2018, trading 1,579 units of PBIO stock currently worth $3,553.
What does Pressure BioSciences do?
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
What does Pressure BioSciences's logo look like?
Complete history of Kevin Quinlan stock trades at Anika Therapeutics and Pressure BioSciences
Pressure BioSciences executives and stock owners
Pressure BioSciences executives and other stock owners filed with the SEC include:
-
Richard Schumacher,
Director -
Richard T. Schumacher,
Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director -
Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D.,
Sr. VP of Engineering -
Dr. Alexander V. Lazarev,
Chief Science Officer -
Daniel Shea,
Chief Financial Officer -
Michael Urdea,
Independent Director -
Kevin Pollack,
Independent Director -
Vito Mangiardi,
Independent Director -
Jeffery Peterson,
Independent Chairman of the Board -
John B. Hollister,
Director of Sales & Marketing -
Alexander V Lazarev,
Director -
Bradford Addison Young,
Chief Commerical Officer -
Jeffrey N Peterson,
Director -
Richard Thomley,
Chief Financial Officer -
Joseph Luis Jr Damasio,
VP of Finance -
Calvin Albert Saravis,
Director -
Matthew B Potter,
Vice President of Sales -
Steven E Hebert,
CFO / VP Finance / Asst. Treas -
J Donald Payne,
Director -
Edward H Myles,
Vice President of Finance/CFO -
Edmund Y Ting,
Senior VP of Engineering -
Kevin W Quinlan,
Director -
P Thomas Vogel,
Director -
R Wayne Fritzsche,
Director -
Alan D Rosenson,
Director -
Nathan Lawrence,
VP of Marketing and Sales -
Gregory Gene Freitag,
Director -
Clayton Acss Llc/Il Struve,
-
Alan Ira Goldberg,
Director